Control Bionics Ltd
ASX:CBL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.027
0.079
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Control Bionics Ltd
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-07. The firm is principally engaged in development, commercialization and sale of assistive communications technology systems namely NeuroNode within the disability sector. The Group’s core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment and external control of other devices. Its NeuroNode Trilogy system combines its NeuroNode with eye-gaze technology to create a communication system. Its NeuroNode3 combines the NeuroNode wearable device with operating systems and is suitable for users with severe impairment. Its geographical locations consist of Australia, which is engaged in sales of Trilogy units and components in Australia, and North America, which is engaged in manufacturing and sales of Trilogy units and components in North America.
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-07. The firm is principally engaged in development, commercialization and sale of assistive communications technology systems namely NeuroNode within the disability sector. The Group’s core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment and external control of other devices. Its NeuroNode Trilogy system combines its NeuroNode with eye-gaze technology to create a communication system. Its NeuroNode3 combines the NeuroNode wearable device with operating systems and is suitable for users with severe impairment. Its geographical locations consist of Australia, which is engaged in sales of Trilogy units and components in Australia, and North America, which is engaged in manufacturing and sales of Trilogy units and components in North America.
